Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Beat, Knusel"'
Autor:
Michelle L, O'Donoghue, Robert S, Rosenson, Baris, Gencer, J Antonio G, López, Norman E, Lepor, Seth J, Baum, Elmer, Stout, Daniel, Gaudet, Beat, Knusel, Julia F, Kuder, Xinhui, Ran, Sabina A, Murphy, Huei, Wang, You, Wu, Helina, Kassahun, Marc S, Sabatine, A, Carlisle
Publikováno v:
O'Donoghue, Michelle L; Rosenson, Robert S; Gencer, Baris; López, J Antonio G; Lepor, Norman E; Baum, Seth J; Stout, Elmer; Gaudet, Daniel; Knusel, Beat; Kuder, Julia F; Ran, Xinhui; Murphy, Sabina A; Wang, Huei; Wu, You; Kassahun, Helina; Sabatine, Marc S (2022). Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. New England journal of medicine NEJM, 387(20), pp. 1855-1864. Massachusetts Medical Society MMS 10.1056/NEJMoa2211023
BACKGROUND Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. METHODS We conducted a randomized, double-blind, placebo-controll
Autor:
Michelle L. O'Donoghue, Robert S. Rosenson, Baris Gencer, J. Antonio, G. Lopez, Norman E. Lepor, Daniel Gaudet, Seth J. Baum, Elmer Stout, Beat Knusel, Julia Kuder, Xinhui Ran, Sabina Murphy, You Wu, Huei Wang, Helina Kassahun, Marc Steven Sabatine
Publikováno v:
Journal of the American College of Cardiology. 81:1130
Autor:
Michelle L. O'Donoghue, J. Antonio G. López, Beat Knusel, Baris Gencer, Huei Wang, You Wu, Helina Kassahun, Marc S. Sabatine
Publikováno v:
O'Donoghue, Michelle L; G López, J Antonio; Knusel, Beat; Gencer, Baris; Wang, Huei; Wu, You; Kassahun, Helina; Sabatine, Marc S (2022). Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). American Heart Journal, 251, pp. 61-69. Elsevier 10.1016/j.ahj.2022.05.004
BACKGROUND Data support lipoprotein(a) (Lp[Lp(a)]) being a risk factor for atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that markedly reduces Lp(a) production in hepatocytes. STUDY DESIGN The Olpasiran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::688133b46dca9beca1122cdc4cfd8c0d
Autor:
Terje R. Pedersen, Marc S. Sabatine, Ioanna Gouni-Berthold, Beat Knusel, Robert P. Giugliano, Anthony C Keech, Huei Wang, Peter S. Sever, KyungAh Im, Michelle L. O'Donoghue
Publikováno v:
European journal of preventive cardiology. 28(8)
Aims Some trials have reported diminished efficacy for statins in the elderly, and in women compared with men. We examined the efficacy and safety of evolocumab by patient age and sex in the FOURIER trial, the first major cardiovascular outcome trial
Autor:
Beat Knusel, Ransi Somaratne, Jingjing Schneider, Bernd Hohenstein, Dev Datta, Seth J. Baum, Christopher E. Kurtz, Tiziana Sampietro, Patrick M. Moriarty
Publikováno v:
Journal of clinical lipidology. 13(6)
Lipoprotein apheresis (LA) can effectively lower lipoproteins but is an invasive procedure.The objective of this study was to evaluate whether evolocumab can reduce LA requirement in patients undergoing chronic LA.Patients on regular weekly or every-
Autor:
John R. Teerlink, Kenneth Dickstein, Fady I. Malik, Justin A. Ezekowitz, Beat Knusel, John J.V. McMurray, Andrew A. Wolff, Gerasimos Filippatos, Scott M. Wasserman, Jae B. Kim, Marco Metra, G. Michael Felker, John G.F. Cleland, Lei Lei, Piotr Ponikowski
Publikováno v:
Journal of the American College of Cardiology. 67:1444-1455
Background Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure. Objectives This study evaluated the pharmacokinetics, pharmacodynamics, to
Autor:
Eric Bruckert, David Colquhoun, Robert S. Rosenson, Erik S.G. Stroes, Michael Rocco, Rob Scott, Fernando Civeira, Scott M. Wasserman, Beat Knusel, Leslie Cho, Ricardo Dent, David R. Sullivan, Gerald F. Watts, Allen Xue
Publikováno v:
Journal of the American College of Cardiology. 63:2541-2548
Objectives This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate effective statin doses. Background Statin intolerance, which is predo
Autor:
Beat Knusel, Michael J. Koren, Michael A. Bolognese, Jae B. Kim, Thomas Liu, Lei Lei, Scott M. Wasserman, Rob Scott
Publikováno v:
The Lancet. 380:1995-2006
Summary Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases serum LDL-cholesterol (LDL-C) concentrations. We assessed the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients with hypercholesterolaemia in
Autor:
John R, Teerlink, G Michael, Felker, John J V, McMurray, Piotr, Ponikowski, Marco, Metra, Gerasimos S, Filippatos, Justin A, Ezekowitz, Kenneth, Dickstein, John G F, Cleland, Jae B, Kim, Lei, Lei, Beat, Knusel, Andrew A, Wolff, Fady I, Malik, Scott M, Wasserman
Publikováno v:
Journal of the American College of Cardiology. 67(12)
Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure.This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and
Autor:
Jalal K. Ghali, Marc Klapholz, Piotr Ponikowski, William T. Abraham, Stefan D. Anker, Dirk J. van Veldhuisen, Yan Sun, Beat Knusel, Scott M. Wasserman
Publikováno v:
European Journal of Heart Failure, 11(11), 1071-1077. Wiley
Aims To assess the safety and tolerability of darbepoetin alfa (DA) in the treatment of anaemia in heart failure (HF). Methods and results In this pooled analysis of three randomized, double-blind, placebo-controlled studies of anaemic [haemoglobin (